Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 6/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.77 |
| ▸ | PTGES | O14684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | PDE5A | O76074 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | CA3 | P07451 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433466 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL6343096 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| Celecoxib SCHEMBL3708 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| Celecoxib SCHEMBL3669597 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL213784 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL3243744 | 0.86 | PTGS2 (0.77) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL5674001 | 0.86 | PDPK1 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| Celecoxib SCHEMBL6600270 | 0.86 | PTGS2 (0.98) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| Celecoxib SCHEMBL3785427 | 0.86 | PTGS2 (0.98) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| Celecoxib SCHEMBL9998656 | 0.86 | PTGS2 (0.98) | PTGS2PTGS1PDPK1PTGESCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | claimed |
| EP-1296679-B1 | DERMAL THERAPEUTIC SYSTEM CONTAINING NON-STEROIDAL ANTIPHLOGISTICS WITH SELECTIVE COX-2 INHIBITION | LOHMANN THERAPIE SYST LTS (DE) | 2006-03-15 | — | — | EP | claimed |
| US-20050075359-A1 | Large conductance calcium-activated K channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2005-04-07 | — | — | US | claimed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| EP-1400243-A1 | Calcium-activated K channel activator | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-24 | — | — | EP | claimed |
| US-6492411-B1 | TREATING ARTHRITIS; REDUCED SIDE EFFECTS | G. D. SEARLE & CO. | 2002-12-10 | — | — | US | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| US-6413960-B1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS; ACTIVE IN REDUCING PROSTAGLANDIN-INDUCED PAIN AND SWELLING; ANALGESICS; ANTIPYRETICS; ARTHRITIS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2002-07-02 | — | — | US | claimed |
| EP-0731795-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-12-22 | — | — | EP | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| US-20230398072-A1 | CONCENTRATE CONTAINING POORLY SOLUBLE DRUG AND EMULSION PREPARED THEREFROM | BEIJING DELIVERY PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | PTGS2 279/4885PTGS1 539/4885PDPK1 2938/4885 |
| US-20050075359-A1 | Large conductance calcium-activated K channel opener | KCNN3, KCNN2, KCNN1 | PTGS2 806/4885PTGS1 760/4885PDPK1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.